perifosine + bortezomib + dexamethasone

Perifosine + bortezomib + dexamethasone is a combination regimen investigated for the treatment of relapsed or relapsed/refractory multiple myeloma. - **Perifosine** is an oral synthetic alkylphospholipid that acts as a signal transduction modulator, primarily inhibiting the PI3K/Akt pathway[1][2][4][5]. - **Bortezomib** is a reversible proteasome inhibitor, disrupting cellular protein degradation and causing apoptosis in myeloma cells[2][6]. - **Dexamethasone** is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties, commonly used to potentiate anti-myeloma effect[4][6]. Preclinical and phase I/II studies demonstrated encouraging activity, especially in heavily pretreated, bortezomib-exposed patients, with overall response rates up to 41% and median progression-free survival around 6.4 months[4][5][7]. However, a randomized phase III trial was discontinued at interim analysis due to lack of progression-free survival benefit compared to bortezomib + dexamethasone alone[1][2][7]. Main toxicities were hematologic (thrombocytopenia, anemia), hyponatremia, and pneumonia[1][2][4].

Brand names

Velcade (for bortezomib)perifosine and dexamethasone are typically used as generics

Other names

perifosine + bortezomib + dexamethasone